Brought to you by 
SkyePharma applies Geomatrix to King's Altace
09 Dec 2020
Executive Summary
SkyePharma PLC will apply its oral drug delivery technology Geomatrix to King Pharmaceuticals' Altace (ramipril), an ACE inhibitor approved for hypertension, congestive heart failure following a heart attack, and the prevention of stroke, myocardial infarction, and death from cardiovascular events.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SkyePharma applies Geomatrix to King's Altace
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice